Breast surgery for low-grade ductal carcinoma may not improve survival
the ONA take:
According to a new study published in JAMA Surgery, researchers from Brigham and Women's Hospital in Boston, Massachusetts, have found that breast surgery performed at or shortly after a diagnosis of low-grade ductal carcinoma in-situ (DCIS) experienced no difference in survival compared with those who did not receive surgery.
For the retrospective analysis, researchers analyzed data from over 50,000 cases of DCIS available from the Surveillance, Epidemiology and End Results (SEER) database between 1998 and 2011. All patients were treated at Dana-Farber/Brigham and Women's Cancer Center.
Results showed that patients with low-grade DCIS who did not receive surgery at or shortly after diagnosis had a 10-year survival rate of 98.8% compared with 98.6% for those who did receive surgery; however, women with intermediate- or high-grade DCIS, the survival rate was significantly higher for those who had surgery versus those who did not.
The researchers note that a prospective clinical trial is warranted before it can be concluded that breast surgery should be avoided for women with low-grade DCIS.
Breast surgery performed at or shortly after a diagnosis of low-grade ductal carcinoma in-situ experienced no difference in survival.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|